{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T14:24:48Z","timestamp":1783088688204,"version":"3.54.6"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,8,1]],"date-time":"2015-08-01T00:00:00Z","timestamp":1438387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Primus Pharmaceuticals, Inc."},{"name":"Designs for Health, Inc."}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","plefa.com","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Prostaglandins, Leukotrienes and Essential Fatty Acids"],"published-print":{"date-parts":[[2015,8]]},"DOI":"10.1016\/j.plefa.2015.05.002","type":"journal-article","created":{"date-parts":[[2015,5,30]],"date-time":"2015-05-30T08:47:35Z","timestamp":1432975655000},"page":"41-46","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Safety and lipid-altering efficacy of a new omega-3 fatty acid and antioxidant-containing medical food in men and women with elevated triacylglycerols"],"prefix":"10.1016","volume":"99","author":[{"given":"K.C.","family":"Maki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.G.","family":"Geohas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.R.","family":"Dicklin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Huebner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.K.","family":"Udani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.plefa.2015.05.002_bib1","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1161\/CIR.0b013e3182160726","article-title":"Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association","volume":"123","author":"Miller","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.plefa.2015.05.002_bib2","first-page":"e28","article-title":"Heart disease and stroke statistics \u2013 2014 update: a report from the American Heart Association","volume":"129","author":"Go","year":"2014","journal-title":"Circulation"},{"issue":"25 Pt B","key":"10.1016\/j.plefa.2015.05.002_bib3","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1016\/j.jacc.2013.11.002","volume":"63","author":"Stone","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.plefa.2015.05.002_bib4","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.jacl.2015.02.003","article-title":"National Lipid Association recommendations for patient-centered management of dyslipidemia: part 1 \u2013 full report","volume":"8","author":"Jacobson","year":"2015","journal-title":"J. Clin. Lipidol."},{"key":"10.1016\/j.plefa.2015.05.002_bib5","unstructured":"Lovaza Prescribing Information. \u3008https:\/\/www.gsksource.com\/gskprm\/htdocs\/documents\/LOVAZA-PI-PIL.PDF\u3009."},{"key":"10.1016\/j.plefa.2015.05.002_bib6","unstructured":"Vascepa Prescribing Information. \u3008http:\/\/www.vascepa.com\/full-prescribing-information.pdf\u3009."},{"key":"10.1016\/j.plefa.2015.05.002_bib7","unstructured":"Epanova Prescribing Information. \u3008http:\/\/www1.astrazeneca-us.com\/pi\/epanova.pdf\u3009."},{"key":"10.1016\/j.plefa.2015.05.002_bib8","unstructured":"Omtryg Prescribing Information. \u3008http:\/\/www.drugs.com\/pro\/omtryg.html\u3009."},{"key":"10.1016\/j.plefa.2015.05.002_bib9","unstructured":"Omega-3-Acid Ethyl Esters Capsules Prescribing Information. \u3008http:\/\/www.tevagenerics.com\/product\/omega-3-acid-ethyl-esters-capsules-usp?audience=hcp\u3009."},{"key":"10.1016\/j.plefa.2015.05.002_bib10","doi-asserted-by":"crossref","first-page":"216","DOI":"10.5551\/jat1994.7.216","article-title":"Inhibition of low-density lipoprotein oxidation by astaxanthin","volume":"7","author":"Iwamoto","year":"2000","journal-title":"J. Atheroscler. Thromb."},{"issue":"Suppl. 10A","key":"10.1016\/j.plefa.2015.05.002_bib11","doi-asserted-by":"crossref","first-page":"S58D","DOI":"10.1016\/j.amjcard.2008.02.010","article-title":"Astaxanthin: a novel potential treatment for oxidative stress and inflammation in cardiovascular disease","volume":"101","author":"Pashkow","year":"2008","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.plefa.2015.05.002_bib12","doi-asserted-by":"crossref","first-page":"3030","DOI":"10.1016\/j.fct.2008.05.038","article-title":"Safety assessment of astaxanthin-rich microalgae biomass: acute and subchronic toxicity in rats","volume":"46","author":"Stewart","year":"2008","journal-title":"Food Chem. Toxicol."},{"key":"10.1016\/j.plefa.2015.05.002_bib13","doi-asserted-by":"crossref","first-page":"447","DOI":"10.3390\/md9030447","article-title":"Astaxanthin: a potential therapeutic agent in cardiovascular disease","volume":"9","author":"Fassett","year":"2011","journal-title":"Mar. Drugs"},{"key":"10.1016\/j.plefa.2015.05.002_bib14","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1002\/mnfr.201000414","article-title":"Potential health-promoting effects of astaxanthin: a high-value carotenoid mostly from microalgae","volume":"55","author":"Yuan","year":"2011","journal-title":"Mol. Nutr. Food Res."},{"key":"10.1016\/j.plefa.2015.05.002_bib15","doi-asserted-by":"crossref","first-page":"10544","DOI":"10.1016\/S0021-9258(18)67419-8","article-title":"The structure of an inhibitor of cholesterol biosynthesis isolated from barley","volume":"261","author":"Qureshi","year":"1986","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.plefa.2015.05.002_bib16","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1007\/BF02536620","article-title":"Response of hypercholesterolemic patients to administration of tocotrienols","volume":"30","author":"Qureshi","year":"1995","journal-title":"Lipids"},{"key":"10.1016\/j.plefa.2015.05.002_bib17","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1093\/jn\/126.2.389","article-title":"Dietary alpha-tocopherol attenuates the impact of gamma-tocotrienol on hepatic 3-hydroxy-3-methylglutaryl coenzyme A reductase activity in chickens","volume":"126","author":"Qureshi","year":"1996","journal-title":"J. Nutr."},{"key":"10.1016\/j.plefa.2015.05.002_bib18","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S0021-9150(01)00619-0","article-title":"Dose-dependent suppression of serum cholesterol by a tocotrienol-rich fraction (TRF25) of rice bran in hypercholesterolemic humans","volume":"161","author":"Qureshi","year":"2002","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.plefa.2015.05.002_bib19","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/0005-2760(93)90092-N","article-title":"Comparative antioxidant activity of tocotrienols and other natural lipid-soluble antioxidants in a homogeneous system and in rat and human lipoproteins","volume":"1166","author":"Suarna","year":"1993","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.plefa.2015.05.002_bib20","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/S0278-6915(01)00025-4","article-title":"Oral toxicity of a tocotrienol preparation in rats","volume":"39","author":"Nakamura","year":"2001","journal-title":"Food Chem. Toxicol."},{"key":"10.1016\/j.plefa.2015.05.002_bib21","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1016\/j.lfs.2005.12.001","article-title":"Tocotrienols: vitamin E beyond tocopherols","volume":"78","author":"Sen","year":"2006","journal-title":"Life Sci."},{"key":"10.1016\/j.plefa.2015.05.002_bib22","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.mam.2007.03.001","article-title":"Tocotrienols in health and disease: the other half of the natural vitamin E family","volume":"28","author":"Sen","year":"2007","journal-title":"Mol. Asp. Med."},{"key":"10.1016\/j.plefa.2015.05.002_bib23","doi-asserted-by":"crossref","first-page":"48238","DOI":"10.1074\/jbc.M405442200","article-title":"Inhibition of geranylgeranylation mediates the effects of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors on microglia","volume":"279","author":"Bi","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.plefa.2015.05.002_bib24","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1111\/j.1476-5381.2009.00465.x","article-title":"Geranylgeraniol prevents the cytotoxic effects of mevastatin in THP-1 cells without decreasing the beneficial effects on cholesterol synthesis","volume":"158","author":"Campia","year":"2009","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.plefa.2015.05.002_bib25","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1177\/000456326900600108","article-title":"Determination of glucose in blood using glucose oxidase with an alternative oxygen acceptor","volume":"6","author":"Trinder","year":"1969","journal-title":"Ann. Clin. Biochem."},{"key":"10.1016\/j.plefa.2015.05.002_bib26","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1093\/clinchem\/19.5.476","article-title":"Quantitative determination of serum triglycerides by the use of enzymes","volume":"19","author":"Bucolo","year":"1973","journal-title":"Clin. Chem."},{"key":"10.1016\/j.plefa.2015.05.002_bib27","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1093\/clinchem\/20.4.470","article-title":"Enzymatic determination of total serum cholesterol","volume":"20","author":"Allain","year":"1974","journal-title":"Clin. Chem."},{"key":"10.1016\/j.plefa.2015.05.002_bib28","first-page":"226","article-title":"Enzymatic determination of total cholesterol in serum","volume":"12","author":"Roeschlau","year":"1974","journal-title":"Z. Klin. Chem. Klin. Biochem."},{"key":"10.1016\/j.plefa.2015.05.002_bib29","first-page":"337","article-title":"Reference limits of apolipoprotein A\u2013I and apolipoprotein B using an IFCC standardized immunonephelometric method","volume":"33","author":"Steinmetz","year":"1995","journal-title":"Eur. J. Clin. Chem. Clin. Biochem."},{"key":"10.1016\/j.plefa.2015.05.002_bib30","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1046\/j.1365-2796.2002.01054.x","article-title":"Circulating oxidized low-density lipoprotein (LDL) is associated with risk factors of the metabolic syndrome and LDL size in clinically healthy 58-year old men (AIR study)","volume":"252","author":"Sigurdardottir","year":"2002","journal-title":"J. Intern. Med."},{"issue":"Suppl. 1","key":"10.1016\/j.plefa.2015.05.002_bib31","doi-asserted-by":"crossref","first-page":"S1035.6","DOI":"10.1096\/fasebj.28.1_supplement.1035.6","article-title":"Relationship between baseline triglyceride concentration and triglyceride reduction with 4g\/d long-chain omega-3 acid ethyl esters","volume":"28","author":"Nieman","year":"2014","journal-title":"FASEB J."},{"key":"10.1016\/j.plefa.2015.05.002_bib32","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/j.amjcard.2012.05.031","article-title":"Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study)","volume":"110","author":"Ballantyne","year":"2012","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.plefa.2015.05.002_bib33","doi-asserted-by":"crossref","first-page":"71i","DOI":"10.1016\/j.amjcard.2005.12.029","article-title":"Clinical overview of Omacor-a concentrated formulation of omega-3 polyunsaturated fatty acids","volume":"98","author":"Bays","year":"2006","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.plefa.2015.05.002_bib34","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.amjcard.2011.04.015","article-title":"Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the Multi-center, plAcebo-controlled, Randomized, double blINd, 12-week study with an open-label Extension [MARINE] trial)","volume":"108","author":"Bays","year":"2011","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.plefa.2015.05.002_bib35","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.jacl.2012.07.001","article-title":"Icosapent ethyl, a pure EPA omega-3 fatty acid: effects on lipoprotein particle concentration and size in patients with very high triglyceride levels (the MARINE study)","volume":"6","author":"Bays","year":"2012","journal-title":"J. Clin. Lipidol."},{"key":"10.1016\/j.plefa.2015.05.002_bib36","doi-asserted-by":"crossref","first-page":"177","DOI":"10.2217\/fca.13.4","article-title":"Epanova\u00ae and hypertriglyceridemia: pharmacological mechanisms and clinical efficacy","volume":"9","author":"Kataoka","year":"2013","journal-title":"Future Cardiol."},{"key":"10.1016\/j.plefa.2015.05.002_bib37","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jacl.2013.10.003","article-title":"Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia: the EpanoVa fOr Lowering Very high triglyceridEs (EVOLVE) trial","volume":"8","author":"Kastelein","year":"2014","journal-title":"J. Clin. Lipidol."},{"key":"10.1016\/j.plefa.2015.05.002_bib38","doi-asserted-by":"crossref","first-page":"399","DOI":"10.2217\/clp.14.39","article-title":"Prescription omega-3 carboxylic acids for the treatment of severe hypertriglyceridemia","volume":"9","author":"Maki","year":"2014","journal-title":"Clin. Lipidol."},{"key":"10.1016\/j.plefa.2015.05.002_bib39","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1016\/j.amjcard.2009.12.063","article-title":"COMBination of prescription Omega-3 with Simvastatin (COMBOS) Investigators, Baseline lipoprotein lipids and low-density lipoprotein cholesterol response to prescription omega-3 acid ethyl ester added to simvastatin therapy","volume":"105","author":"Maki","year":"2010","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.plefa.2015.05.002_bib40","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1017\/S0029665111000061","article-title":"The differential effects of EPA and DHA on cardiovascular risk factors","volume":"70","author":"Cottin","year":"2011","journal-title":"Proc. Nutr. Soc."},{"key":"10.1016\/j.plefa.2015.05.002_bib41","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1007\/s11883-011-0210-3","article-title":"Effects of eicosapentaenoic acid versus docosahexaenoic acid on serum lipids: a systematic review and meta-analysis","volume":"13","author":"Wei","year":"2011","journal-title":"Curr. Atheroscler. Rep."},{"key":"10.1016\/j.plefa.2015.05.002_bib42","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.jacl.2011.10.018","article-title":"Effects of eicosapentaenoic acid and docosahexaenoic acid on low-density lipoprotein cholesterol and other lipids: a review","volume":"6","author":"Jacobson","year":"2012","journal-title":"J. Clin. Lipidol."},{"key":"10.1016\/j.plefa.2015.05.002_bib43","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S0021-9150(98)00301-3","article-title":"Correlation of serum triglyceride and its reduction by omega-3 fatty acids with lipid transfer activity and the neutral lipid composition of high-density and low-density lipoproteins","volume":"143","author":"Pownall","year":"1999","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.plefa.2015.05.002_bib44","doi-asserted-by":"crossref","first-page":"425","DOI":"10.2217\/clp.09.34","article-title":"Omega-3 fatty acids for the treatment of elevated triglycerides","volume":"4","author":"Maki","year":"2009","journal-title":"Clin. Lipidol."},{"key":"10.1016\/j.plefa.2015.05.002_bib45","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.jacl.2009.08.001","article-title":"Effects of prescription omega-3-acid ethyl esters on lipoprotein particle concentrations, apolipoproteins AI and CIII, and lipoprotein-associated phospholipase A2 mass in statin-treated subjects with hypertriglyceridemia","volume":"3","author":"Davidson","year":"2009","journal-title":"J. Clin. Lipidol."},{"key":"10.1016\/j.plefa.2015.05.002_bib46","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.jacl.2011.09.001","article-title":"Effects of prescription omega-3-acid ethyl esters, coadministered with atorvastatin, on circulating levels of lipoprotein particles, apolipoprotein CIII, and lipoprotein-associated phospholipase A2 mass in men and women with mixed dyslipidemia","volume":"5","author":"Maki","year":"2011","journal-title":"J. Clin. Lipidol."},{"key":"10.1016\/j.plefa.2015.05.002_bib47","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.amjcard.2008.03.078","article-title":"Effects of adding prescription omega-3 acid ethyl esters to simvastatin (20mg\/day) on lipids and lipoprotein particles in men and women with mixed dyslipidemia","volume":"102","author":"Maki","year":"2008","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.plefa.2015.05.002_bib48","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/978-94-007-7920-4_9","article-title":"Oxidative modification of lipoproteins","volume":"77","author":"Arai","year":"2014","journal-title":"Subcell. Biochem."},{"key":"10.1016\/j.plefa.2015.05.002_bib49","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1016\/j.clinthera.2007.07.018","volume":"29","author":"Davidson","year":"2007","journal-title":"Clin. Ther."},{"key":"10.1016\/j.plefa.2015.05.002_bib50","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1016\/j.clinthera.2013.07.420","article-title":"A highly bioavailable omega-3 free fatty acid formulation improves the cardiovascular risk profile in high-risk, statin-treated patients with residual hypertriglyceridemia (the ESPRIT trial)","volume":"35","author":"Maki","year":"2013","journal-title":"Clin. Ther."},{"key":"10.1016\/j.plefa.2015.05.002_bib51","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.plefa.2013.09.011","article-title":"Long chain omega-3 fatty acid immunomodulation and the potential for adverse health outcomes","volume":"89","author":"Fenton","year":"2013","journal-title":"Prostaglandins Leukot. Essent. Fatty Acids"},{"key":"10.1016\/j.plefa.2015.05.002_bib52","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1254\/jphs.10R33FM","article-title":"Neuroprotective and ameliorative actions of polyunsaturated fatty acids against neuronal diseases: beneficial effect of docosahexaenoic acid on cognitive decline in Alzheimer\u05f3s disease","volume":"116","author":"Hashimoto","year":"2011","journal-title":"J. Pharmacol. Sci."},{"key":"10.1016\/j.plefa.2015.05.002_bib53","doi-asserted-by":"crossref","first-page":"672","DOI":"10.3945\/an.113.004556","article-title":"Omega-3 fatty acids in the prevention of cognitive decline in humans","volume":"4","author":"Cederholm","year":"2013","journal-title":"Adv. Nutr."},{"key":"10.1016\/j.plefa.2015.05.002_bib54","doi-asserted-by":"crossref","first-page":"450","DOI":"10.2174\/1871527311312040003","article-title":"N-3 (omega-3) polyunsaturated fatty acids in the pathophysiology and treatment of depression: pre-clinical evidence","volume":"12","author":"Levant","year":"2013","journal-title":"CNS Neurol. Disord. Drug Targets"},{"key":"10.1016\/j.plefa.2015.05.002_bib55","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.3390\/nu6031293","article-title":"Neuroprotective properties of the marine carotenoid astaxanthin and omega-3 fatty acids, and perspectives of the natural combination of both in krill oil","volume":"6","author":"Barros","year":"2014","journal-title":"Nutrients"},{"issue":"3 Suppl.","key":"10.1016\/j.plefa.2015.05.002_bib56","doi-asserted-by":"crossref","first-page":"314S","DOI":"10.1080\/07315724.2010.10719846","article-title":"Palm oil-derived natural vitamin E alpha-tocotrienol in brain health and disease","volume":"29","author":"Sen","year":"2010","journal-title":"J. Am. Coll. Nutr."},{"key":"10.1016\/j.plefa.2015.05.002_bib57","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.nut.2013.11.001","article-title":"Can w-3 fatty acids and tocotrienol-rich vitamin E reduce symptoms of neurodevelopmental disorders?","volume":"30","author":"Gumpricht","year":"2014","journal-title":"Nutrition"}],"container-title":["Prostaglandins, Leukotrienes and Essential Fatty Acids"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0952327815001192?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0952327815001192?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,9]],"date-time":"2024-06-09T08:27:14Z","timestamp":1717921634000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0952327815001192"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8]]},"references-count":57,"alternative-id":["S0952327815001192"],"URL":"https:\/\/doi.org\/10.1016\/j.plefa.2015.05.002","relation":{},"ISSN":["0952-3278"],"issn-type":[{"value":"0952-3278","type":"print"}],"subject":[],"published":{"date-parts":[[2015,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and lipid-altering efficacy of a new omega-3 fatty acid and antioxidant-containing medical food in men and women with elevated triacylglycerols","name":"articletitle","label":"Article Title"},{"value":"Prostaglandins, Leukotrienes and Essential Fatty Acids","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.plefa.2015.05.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}